Stockreport

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Abbott Laboratories  (ABT) 
Last abbott laboratories earnings: 4/16 07:30 am Check Earnings Report
US:NYSE Investor Relations: abbott.com/investors.html
PDF U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy ran [Read more]